Angiotensin II vs its type I antagonists: Conformational requirements for receptor binding assessed from NMR spectroscopic and receptor docking experiments

Journal of Medicinal Chemistry

Volumn 45, Issue 20, 2002, Pages 4410-4418

  Wilkes, Brian C ^a   Masaro, Laurent ^c   Schiller, Peter W ^a,c   Carpenter, Katharine A ^b,c  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN II [1 GLUTAMINE 2 GLYCINE 5 VALINE 8 VALINE]; ANGIOTENSIN II [1-7]AMIDE[1 SARCOSINE]; ANGIOTENSIN II ANTAGONIST; ASPARTIC ACID; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HISTIDINE; LOSARTAN; LYSINE; PHENYLALANINE; SARALASIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG CONFORMATION; DRUG RECEPTOR BINDING; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR OVERHAUSER EFFECT; SPECTROSCOPY;

ANGIOTENSIN I; ANGIOTENSIN II; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; RECEPTORS, ANGIOTENSIN; SARALASIN; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037179642     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0103155     Document Type: Article

References (48)

1. Timmermans, P. B.; Wong, P. C.; Chiu, A. T.; Herblin, W. F.; Benfield, P.; Carini, D. J.; Lee, R. J.; Wexler, R. R.; Saye, J. A.; Smith, R. D. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 1993, 45, 205-251.
2. Fukamizu, A.; Murakami, K. Activated and inactivated reninangiotensin system in transgenic animals: from genes to blood pressure. Lab. Anim. Sci. 1997, 47, 127-131.
3. Murphy, T. J.; Alexander, R. W.; Griendling, K. K.; Runge, M. S.; Bernstein, K. E. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991, 351, 233-236.
4. Sasaki, K.; Yamano, Y.; Bardhan, S.; Iwai, N.; Murray, J. J.; Hasegawa, M.; Matsuda, Y; Inagami, T. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 1991, 351, 230-233.
5. Mukoyama, M.; Nakajima, M.; Horiuchi, M.; Sasamura, H.; Pratt, R. E.; Dzau, V. J. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J. Biol. Chem. 1993, 268, 24539-24542.
6. Kambayashi, Y.; Bardhan, S.; Takahashi, K.; Tsuzuki, S.; Inui, H.; Hamakubo, T.; Inagami, T., Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J. Biol. Chem. 1993, 268, 24543-24546.
7. Timmermans, P. B.; Inagami, T.; Saavedra, J. M.; Ardaillou, R.; Rosenfeld, C. R.; Mendelsohn, F. A. O. Pharmacological Sciences: Perspectives for research and Therapy in the late 1990s; Cuello, A. C., Collier, B., Eds.; Switzerland, 1995.
8. Ondetti, M. A.; Rubin, B.; Cushman, D. W. Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science 1977, 196, 441-444.
9. Patchett, A. A.; Harris, E.; Tristram, E. W.; Wyvratt, M. J.; Wu, M. T.; Taub, D.; Peterson, E. R.; Ikeler, T. J.; ten Broeke, J.; Payne, L. G.; Ondeyka, D. L.; Thorsett, E. D.; Greenlee, W. J.; Lohr, N. S.; Hoffsommer, R. D.; Joshua, H.; Ruyle, W. V.; Rothrock, J. W.; Aster, S. D.; Maycock, A. L.; Robinson, F. M.; Hirschmann, R.; Sweet, C. S.; Ulm, E. H.; Gross, D. M.; Vassil, T. C.; Stone, C. A. A new class of angiotensin-converting enzyme inhibitors. Nature 1980, 288, 280-283.
10. Aumelas, A.; Sakarellos, C.; Lintner, K.; Fermandjian, S.; Khosla, M. C.; Smeby, R. R.; Bumpus, M. F. Studies on angiotensin II and analogues: impact of substitution in position 8 on conformation and activity. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 1881-1885.
11. Rioux, F.; Park, W. K.; Regoli, D. Role of the C-terminal group for the biological activities of angiotensin. Can. J. Physiol. Pharmacol. 1975, 53, 383-391.
12. Turker, R. K.; Hall, M. M.; Yamamoto, M.; Sweet, C. S.; Bumpus, F. M. A new, long-lasting competitive inhibitor of angiotensin. Science 1972, 177, 1203-1205.
13. Khosla, M. C.; Leese, R. A.; Maloy, W. L.; Ferreira, A. T.; Smeby, R. R.; Bumpus, F. M. Synthesis of some analogues of angiotensin II as specific antagonists of the parent hormone. J. Med. Chem. 1972, 15, 792-795.
14. Duncia, J. V.; Chiu, A. T.; Carini, D. J.; Gregory, G. B.; Johnson, A. L.; Price, W. A.; Wells, G. J.; Wong, P. C.; Calabrese, J. C.; Timmermans, P. B. The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives. J. Med. Chem. 1990, 33, 1312-1329.
15. Duncia, J. V.; Carini, D. J.; Chiu, A. T.; Johnson, A. L.; Price, W. A.; Wong, P. C.; Wexler, R. R.; Timmermans, P. B. The discovery of an DuP 753, a potent, orally active nonpeptide angiotensin II antagonist. Med. Res. Rev. 1992, 12, 149-191.
16. Scanlon, M. N.; Matsoukas, J. M.; Franklin, K. J.; Moore, G. J. A new approach to angiotensin antagonists: methylation of the tyrosine hydroxyl in angiotensin II. Life Sci. 1984, 34, 317-321.
17. Peach, M. J. Structural features of angiotensin II which are important for biologic activity. Kidney Int., Suppl. 1979, 9, S3-S6.
18. Munoz-Ramirez, H.; Khosla, M. C.; Hall, M. M.; Bumpus, F. M.; Khairallah, P. A. In vitro and in vivo studies of (1-sarcosine, 8-threonine) angiotensin II. Res. Commun. Chem. Path. Pharmacol. 1976, 13, 649-663.
19. Moore, G. J.; Franklin, K. J.; Nystrom, D. M.; Goghari, M. H. Structure-desensitization relationships of angiotensin analogues in the rat isolated uterus. Can. J. Physiol. Pharmacol. 1985, 63, 996-971.
20. Matsoukas, J. M.; Agelis, G.; Hondrelis, J.; Yamdagni, R.; Wu, Q.; Ganter, R.; Smith, J. R.; Moore, D.; Moore, G. J. Synthesis and biological activities of angiotensin II, Sarilesin, and Sarmesin analogues containing Aze or Pip at position 7. J. Med. Chem. 1993, 36, 904-911.
21. Matsoukas, J. M.; Goghari, M. H.; Scanlon, M. N.; Franklin, K. J.; Moore, G. J. Synthesis and biological activities of analogues of angiotensins II and III containing O-methyltyrosine and D-tryptophan. J. Med. Chem. 1985, 28, 780-783.
22. Rosowsky, A.; Forsch, R. A.; Freisheim, J. H.; Moran, R. G. A Carboxy-terminus truncated analogue of angiotensin II, [Sar1]angiotensin II-(1-7)-amide, provides an entry to a new class of angiotensin II antagonists. J. Med. Chem. 1989, 32, 520-522.
23. Carpenter, K. A.; Wilkes, B. C.; Schiller, P. W. The octapeptide angiotensin II adopts a well-defined structure in a phospholipid environment. Eur. J. Biochem. 1998, 251, 448-453.
24. Garcia, K. C.; Ronco, P. M.; Verroust, P. J.; Brünger, A. T.; Amzel, L. M. Three-dimensional structure of an Angiotensin II-Fab complex at 3 Å: hormone recognition by an anti-idiotypic antibody. Science 1992, 257, 502-507.
25. Cho, N.; Asher, S. A. Biospectroscopy 1996, 2, 71-82.
26. Matsoukas, J. M.; Hondrelis, J.; Keramida, M.; Mavromoustakos, T.; Makriyannis, A.; Yamdagni, R.; Wu, Q.; Moore, G. J. Role of the NH2-terminal domain of angiotensin II (ANG II) and [Sar1]angiotensin II on conformation and activity. NMR evidence for aromatic ring clustering and peptide backbone folding compared with [des-1,2,3]angiotensin II. J. Biol. Chem. 1994, 269, 5303-5312.
27. Moore, G. J. Kinetics of acetylation-deacetylation of angiotensin II. Intramolecular interactions of the tyrosine and histidine sidechains. Int. J. Pept. Protein Res. 1985, 26, 469-481.
28. Matsoukas, J. M.; Agelis, G.; Wahhab, A.; Hondrelis, J.; Panagiotopoulos, D.; Yamdagni, R.; Wu, Q.; Mavromoustakos, T.; Maia, H. L.; Ganter, R. Differences in backbone structure between angiotensin II agonists and type I antagonists. J. Med. Chem. 1995, 38, 4660-4669.
29. Moore, G. J.; Ganter, R. C.; Franklin, K. J. Angiotensin "antipeptides": (-)messenger RNA complementary to human angiotensin II (+)messenger RNA encodes an angiotensin receptor antagonist. Biochem. Biophys. Res. Commun. 1989, 160, 1387-1391.
30. Goormaghtigh, E.; Cabiaux, V.; Ruysschaert, J. M. Determination of soluble and membrane protein structure by Fourier Transform Infrared Spectroscopy. In Sub-cellular Biochemistry 23; Hilderson, H. J., Ralston, G. B., Eds.; Plenum Press: New York, 1994; Chapter 8, pp 329-362.
31. Mantsch, H. H.; Perczel, A.; Hollósi, M.; Fasman, G. D. Characterization of beta-turns in cyclic hexapeptides in solution by Fourier transform IR spectroscopy. Biopolymers 1993, 33, 201-207.
32. Wilkes, B. C.; Carpenter, K. A.; Schiller, P. W. Flexible docking of Angiotensin II in its lipid bound conformation to the AT1 receptor. In "Peptides 1998", Proceedings of the 25th European Peptide Symposium; Bajusz, S., Hudecz, F., Eds.; Academia Kiado: Budapest, Hungary, 1999; pp 644-645.
33. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. 2000 Crystal structure of Rhodopsin: A G protein-coupled receptor. Science 2000, 289, 739-745.
34. Nikiforovich, G. V.; Kao, J. L. F.; Plucinska, K.; Zhang, W. J.; Marshall, G. R. Conformational analysis of two cyclic analogues of angiotensin II: implications for the biologically active conformation. Biochemistry 1994, 33, 3591-3598.
35. Joseph, M. P.; Maigret, B.; Sheraga, H. A. Proposals for the angiotensin II receptor-bound conformation by comparative computer modeling of AII and cyclic analogues. Int. J. Pept. Protein Res. 1995, 46, 514-526.
36. Schmidt, B.; Lindman, S.; Tong, W.; Lindeberg, G.; Gogoll, A.; Lai, Z.; Thornwall, M.; Synnergren, B.; Nilsson, A.; Welch, C. J.; Sohtell, M.; Westerlund, C.; Nyberg, F.; Karlen, A. Design, Synthesis, and Biological Activities of Four Angiotensin II Receptor Ligands with g-turn Mimetics Replacing Amino Acid Residues 3-5. J. Med Chem. 1997, 40, 903-919.
37. Bumpus, F. M.; Khosla, M. C. In Hypertension: Physiology and Treatment; Genest, J., Koiw, E., Kuchel, O., Eds.; McGraw-Hill: New York, 1977; pp 183-206.
38. Marshall, G. R.; Bosshard, H. E.; Vine, W. H.; Glickson, J. D.; Needleman, P. In Recent Advances in Renal Physiology and Pharmacology; Wesson, L. G., Fanelli, G. M., Jr., Eds.; University Park Press: Baltimore, 1974; pp 215-256.
39. Regoli, D.; Rioux, F.; Park, W. K.; Choi, C. Role of the N-terminal amino acid for the biological activities of angiotensin and inhibitory analogues. Can. J. Physiol. Pharmacol. 1974, 52, 39-49.
40. Capponi, A. M.; Catt, K. J. Angiotensin II receptors in adrenal cortex and uterus. Binding and activation properties of angiotensin analogues. J. Biol. Chem. 1979, 254, 5120-5127.
41. Mavromoustakos, T.; Kolocouris, A.; Zervou, M.; Roumelioti, P.; Matsoukas, J.; Weisemann, R. An effort to understand the molecular basis of hypertension through the study of conformational analysis of Losartan and Sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations. J. Med. Chem. 1999, 42, 1714-1722.
42. Feng, Y. H.; Noda, K.; Saad, Y.; Liu, X. P.; Husain, A.; Karnik, S. S. The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism. J. Biol. Chem. 1995, 270, 12846-12850.
43. Yamano, Y.; Ohyama, K.; Kikyo, M.; Sano, T.; Nakagomi, Y.; Inoue, Y.; Nakamura, N.; Morishima, I.; Guo, D. F.; Hamakubo, T. Mutagenesis and the molecular modeling of the rat angiotensin II receptor (AT1). J. Biol. Chem. 1995, 270, 14024-14030.
44. Noda, K.; Saad, Y.; Karnik, S. S. Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation. J. Biol. Chem. 1995, 270, 28511-28514.
45. Noda, K.; Saad, Y.; Kinoshita, A.; Boyle, T. P.; Graham, R. M.; Hussain, A.; Karnik, S. S. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J. Biol. Chem. 1995, 270, 2284-2289.
46. Wexler, R. R.; Greenlee, W. J.; Irvin, J. D.; Goldberg, M. R.; Prendergast, K.; Smith, R. D.; Timmermans P. B. M. W. M. Nonpeptide angiotensin II receptors antagonists: The next generation in antihypertensive therapy. J. Med. Chem. 1996, 39, 625-656.
47. Bovy, P. R.; Trapani, A. J.; McMahon, E. G.; Palomo, M. A carboxy-terminus truncated analogue of angiotensin II, [Sar1]angiotensin II-(1-7)-amide, provides an entry to a new class of angiotensin II antagonists. J. Med. Chem. 1989, 32, 520-522.
48. Gasteiger, J.; Marsili, M. Iterative Partial Equalization of Orbital Electronegativity: A Rapid access to Atomic Charges. Tetrahedron 1980, 36, 3219-3228.